Teladoc Health (NYSE:TDOC) CEO Charles Divita III Sells 19,132 Shares

Teladoc Health, Inc. (NYSE:TDOC) CEO Charles Divita III sold 19,132 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the transaction, the chief executive officer owned 389,894 shares in the company, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Charles Divita III also recently made the following trade(s):

• On Wednesday, March 11th, Charles Divita III sold 27,731 shares of Teladoc Health stock. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19.

Teladoc Health Trading Down 6.1%

Shares of NYSE:TDOC opened at $7.08 on Thursday. Teladoc Health, Inc. has a 12-month low of $4.40 and a 12-month high of $9.77. The stock has a market cap of $1.28 billion, a PE ratio of -7.30 and a beta of 2.14. The business has a 50 day moving average of $6.13 and a 200-day moving average of $6.21. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The firm had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, equities research analysts forecast that Teladoc Health, Inc. will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On Teladoc Health

A number of institutional investors have recently modified their holdings of TDOC. IFP Advisors Inc boosted its stake in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after acquiring an additional 2,810 shares in the last quarter. Aster Capital Management DIFC Ltd lifted its holdings in shares of Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock worth $37,000 after acquiring an additional 2,425 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Teladoc Health by 694.5% in the first quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after acquiring an additional 4,945 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Wall Street Analyst Weigh In

TDOC has been the topic of several research reports. Barclays decreased their price target on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Oppenheimer cut their price objective on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, March 3rd. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Thursday, February 26th. Wells Fargo & Company lowered their target price on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, February 26th. Finally, Stifel Nicolaus dropped their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Thursday, February 26th. Five equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.43.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.